Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 481 AL 495

Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease

Jash K, Gondaliya P, Kirave P, Kulkarni B, Sunkaria A, Kalia K.

Drug Dev Res. 2020 Apr;81(2):144-164. doi: 10.1002/ddr.21579. Epub 2019 Aug 5.

Using mouse models to understand Alzheimer's disease mechanisms in the context of trisomy of chromosome 21

Cannavo C, Tosh J, Fisher EMC, Wiseman FK.

Prog Brain Res. 2020;251:181-208. doi: 10.1016/bs.pbr.2019.10.004. Epub 2019 Nov 29.

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Rueda N, Flórez J, Dierssen M, Martínez-Cué C.

Prog Brain Res. 2020;251:245-268. doi: 10.1016/bs.pbr.2019.10.001. Epub 2019 Nov 1.

Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation

Ruthirakuhan M, Herrmann N, Andreazza AC, Verhoeff NPLG, Gallagher D, Black SE, Kiss A, Lanctôt KL.

J Geriatr Psychiatry Neurol. 2020 Jul;33(4):175-184. doi: 10.1177/0891988719874118. Epub 2019 Sep 23.

Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4(-/-): A double-blind, randomized, placebo-controlled crossover trial

Xu Q, Zhang Y, Zhang X, Liu L, Zhou B, Mo R, Li Y, Li H, Li F, Tao Y, Liu Y, Xue C.

Clin Nutr. 2020 Jul;39(7):2092-2105. doi: 10.1016/j.clnu.2019.10.017. Epub 2019 Oct 22.

Alzheimer disease triggered by reversible posterior leukoencephalopathy syndrome

Ros Forteza FJ.

Neurologia (Engl Ed). 2020 May;35(4):279-282. doi: 10.1016/j.nrl.2018.01.006. Epub 2018 Mar 8.

The approach and management of bruxism in Alzheimer's disease: An under-recognized habit that concerns caregivers (innovative practice)

Mathew T, Venkatesh S, Srinivas M.

Dementia (London). 2020 Feb;19(2):461-463. doi: 10.1177/1471301217694249. Epub 2017 Feb 15.

Effectiveness of omega-3 fatty acid supplementation in patients with Alzheimer disease: A systematic review and meta-analysis

Araya-Quintanilla F, Gutiérrez-Espinoza H, Sánchez-Montoya U, Muñoz-Yañez MJ, Baeza-Vergara A, Petersen-Yanjarí M, Fernández-Lecaros L.

Neurologia (Engl Ed). 2020 Mar;35(2):105-114. doi: 10.1016/j.nrl.2017.07.009. Epub 2017 Oct 4.

Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest)

Richards K, Morrison J, Wang YY, Rangel A, Loera A, Hanlon A, Lozano A, Kovach C, Gooneratne N, Fry L, Allen R.

Res Gerontol Nurs. 2020 Nov 1;13(6):280-288. doi: 10.3928/19404921-20200918-01. Epub 2020 Sep 24.

Effects of Myricitrin and Relevant Molecular Mechanisms

Zhang X, Zhang K, Wang Y, Ma R.

Curr Stem Cell Res Ther. 2020;15(1):11-17. doi: 10.2174/1574888X14666181126103338.

Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool

Ha ZY, Mathew S, Yeong KY.

Curr Protein Pept Sci. 2020;21(1):99-109. doi: 10.2174/1389203720666191107094949.

Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease

Singh K, Yadav D, Chauhan PS, Mishra M, Jin JO.

Curr Pharm Des. 2020;26(7):755-763. doi: 10.2174/1381612826666200107161051.

Alzheimer's Disorder: Epigenetic Connection and Associated Risk Factors

Sharma VK, Mehta V, Singh TG.

Curr Neuropharmacol. 2020;18(8):740-753. doi: 10.2174/1570159X18666200128125641.

The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease

Gülcan HO, Orhan IE.

Curr Pharm Des. 2020;26(4):509-516. doi: 10.2174/1381612826666200131103524.

Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's

Nirale P, Paul A, Yadav KS.

Life Sci. 2020 Mar 15;245:117394. doi: 10.1016/j.lfs.2020.117394. Epub 2020 Feb 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias